Stem cell transplant

What it is

Stem cell transplant is a treatment that replaces blood-forming stem cells, often after high-dose therapy, to restore bone marrow function. In modern practice, the stem cells are usually given by intravenous infusion, not by surgery, and the main goal is to help the bone marrow start making healthy blood cells again.

The full medical name is haematopoietic stem cell transplant (HSCT) or haematopoietic stem cell transplant. It is used for some blood cancers, bone marrow failure states, immune disorders, and a few inherited conditions. The stem cells may come from the patient, a matched donor, or stored umbilical cord blood.

A transplant is not a single event but a process that includes disease assessment, donor search if needed, conditioning treatment, stem cell infusion, infection prevention, and long-term follow-up.

Type	Stem cell source	Main purpose	Key issue
Autologous HSCT	Patient's own cells	Allows high-dose chemotherapy, then marrow rescue	No graft-versus-host disease, but no donor immune anti-cancer effect
Allogeneic HSCT	Donor cells	Replaces marrow and can add graft-versus-tumour effect	Risk of graft-versus-host disease
Syngeneic HSCT	Identical twin	Rare option with very close genetic match	Limited availability
Cord blood transplant	Donated umbilical cord blood	Alternative donor source	Slower engraftment is common

In India, HSCT is offered at major cancer and haematology centres, and practical issues such as donor availability, infection risk, blood product support, and cost can strongly affect planning.

How it works

Haematopoietic stem cells are immature cells that can develop into red blood cells, white blood cells, and platelets. Before transplant, the patient usually receives conditioning with chemotherapy, and sometimes radiation, to destroy diseased marrow cells, suppress the immune system, or make space in the marrow for new cells.

After that, the stem cells are infused through a vein, much like a blood transfusion. The cells travel to the bone marrow and, if the transplant succeeds, begin producing new blood cells. This recovery is called engraftment.

The biology differs by transplant type:

1. Autologous transplant: the patient's own stem cells are collected in advance and returned after high-dose treatment. This is mainly a rescue strategy after intensive chemotherapy.
2. Allogeneic transplant: donor stem cells replace the patient's marrow. Donor immune cells may also attack remaining cancer cells, called the graft-versus-tumour or graft-versus-leukaemia effect.
3. Cord blood transplant: uses stem cells from umbilical cord blood. It can be useful when a matched donor is not available, but blood count recovery may take longer.

Matching donor and recipient human leukocyte antigens (HLA) lowers the risk of rejection and graft-versus-host disease, but even well-matched transplants still carry important risks.

Evidence and uses

HSCT is an established treatment for selected malignant and non-malignant diseases. It is not appropriate for every patient with the same diagnosis; timing, disease status, age, organ function, infection history, and donor options all matter.

Common uses include:

• Leukemias such as acute myeloid leukaemia and acute lymphoblastic leukaemia
• Lymphomas including Hodgkin lymphoma and non-Hodgkin lymphoma
• Multiple myeloma, where autologous transplant remains a standard option for many eligible patients
• Aplastic anaemia and other marrow failure syndromes
• Myelodysplastic syndromes and some myeloproliferative neoplasms
• Inherited disorders such as thalassemia and some immune deficiencies
• Sickle cell disease in selected severe cases, usually with allogeneic transplant

The strength of evidence varies by disease. For some conditions, such as multiple myeloma or relapsed lymphoma, autologous transplant has a long-established role. For others, especially rare inherited disorders, evidence often comes from registry studies and specialised centre experience rather than large randomised trials.

Doctors also consider the intent of transplant:

Clinical goal	Example
Curative intent	Some leukaemias, aplastic anaemia, thalassemia
Disease control / longer remission	Multiple myeloma, some lymphomas
Immune system replacement	Certain inherited immune disorders

A transplant team usually weighs expected benefit against transplant-related mortality, relapse risk, and long-term complications. This balance is especially important in older adults and in people with heart, lung, liver, or kidney disease.

Safety and interactions

HSCT is one of the most intensive treatments in cancer and haematology. Serious complications can happen early, during hospitalisation, or months to years later.

Important risks include:

• Severe infections during the period of low white blood cells
• Bleeding from low platelet counts
• Mucositis, which can make eating and swallowing painful
• Organ toxicity, including liver, lung, kidney, and heart problems
• Graft failure or delayed engraftment
• Relapse of the original disease
• Graft-versus-host disease (GVHD) after allogeneic transplant, which can affect skin, gut, liver, lungs, eyes, and other organs

Medicines used around transplant can interact with many common drugs, including antifungals, antibiotics, anticonvulsants, acid-suppressing medicines, and some herbal products or supplements. Immunosuppressants such as tacrolimus or cyclosporine need close monitoring because blood levels can change with interacting medicines.

Patients should tell the transplant team about all prescription drugs, over-the-counter medicines, Ayurvedic products, herbal mixtures, protein powders, and supplements. Some products may increase bleeding risk, affect the liver, or alter drug metabolism. Do not start or stop any supplement during transplant care without checking with the treating clinician or pharmacist.

Vaccination schedules usually need to be rebuilt after transplant because prior immune memory may be lost or weakened.

When to see a clinician

A person being considered for HSCT should be assessed by a transplant specialist early, not only after all standard options have failed. Early referral helps with donor search, fertility counseling, infection screening, and financial planning.

After transplant, urgent medical review is needed for:

• Fever or chills
• New cough or shortness of breath
• Severe diarrhoea or vomiting
• Rash, jaundice, or worsening mouth sores
• Bleeding, bruising, or extreme fatigue
• Reduced urine output, confusion, or severe headache

Even after discharge, follow-up is frequent because complications can appear late. Long-term care may include monitoring for endocrine problems, infertility, cataracts, bone loss, chronic GVHD, and second cancers.

Limitations and open questions

HSCT can be life-saving, but it is not a guaranteed cure and it is not the same as the unproven "stem cell therapies" often advertised online for many unrelated diseases. The transplant discussed here specifically uses blood-forming stem cells for recognised haematology and oncology indications.

Evidence is strong for some diseases and settings, but less certain for others. Questions remain about the best conditioning intensity, how to reduce GVHD without increasing relapse, how to expand donor access, and how to improve outcomes in older or medically complex patients.

Another limitation is access. Outcomes are generally better in experienced centres with strong infection control, transfusion support, HLA typing, and intensive care backup. In India, distance from transplant centres, cost, and the need for prolonged caregiver support can be major barriers.

The decision to proceed with HSCT is individualised. Patients and families should ask about the exact transplant type, expected benefit, short-term mortality risk, relapse risk, donor match quality, likely hospital stay, and long-term quality-of-life effects before consenting.